Higher serum neurofilament light chain levels are linked to increased risk of major vascular events and mortality in atrial fibrillation patients.
2
Each doubling of serum neurofilament light chain levels correlates with a 35% higher risk of major vascular events over an 8-year follow-up.
3
Increased neurofilament levels are associated with higher risks of nonfatal stroke, cardiovascular death, heart failure hospitalization, and all-cause mortality.
4
The association between neurofilament levels and major vascular events is stronger in patients not on anticoagulation and those without prior stroke.
5
The study suggests serum neurofilament light chain may be a useful biomarker for identifying atrial fibrillation patients at higher risk for adverse outcomes.
